Search clinical trials for: simufilam

Total 8 results

Cassava Sciences, Inc.
National Institute on Aging (NIA)

Completed

Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease Patients (PTI-125)

Alzheimer Disease

United States, Canada
Cassava Sciences, Inc.

Not yet recruiting

Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-Simufilam Following a Single Oral Dose in Healthy Male Subjects

Evaluate the Absorption, Metabolism, and Excretion of [ 14C]-Simufilam
Cassava Sciences, Inc.

Active, not recruiting

Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease

Alzheimer's Disease

United States, Canada
Cassava Sciences, Inc.

Enrolling by invitation

Open-label Extension for Phase 3 Clinical Trials of Simufilam

Alzheimer Disease

United States, Canada, Puerto Rico
Cassava Sciences, Inc.
National Institute on Aging (NIA)

Completed

PTI-125 for Mild-to-moderate Alzheimer's Disease Patients

Alzheimer Disease

United States
Cassava Sciences, Inc.
Premier Research Group plc

Active, not recruiting

Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease (REFOCUS-ALZ)

Alzheimer Disease

United States, Korea, Republic of, Canada, Puerto Rico
Cassava Sciences, Inc.
Premier Research Group plc

Active, not recruiting

Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease (RETHINK-ALZ)

Alzheimer Disease

United States, Australia, Canada
Cassava Sciences, Inc.
Worldwide Clinical Trials

Completed

Food Effect and Bioequivalence Study of Simufilam Tablets in Healthy Volunteers

Healthy Volunteers

United States

Search clinical trials for: simufilam

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Indonesia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations